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Abstract
Background: The Human Papillomavirus (HPV) is one of the most common sexually transmitted viruses worldwide.
HPV infection in men is a serious clinical issue as they could be considered as a reservoir for inadvertently
transmitting infection to women. Moreover, genital HPV infection could be a source for anogenital cancers in men.
Methods: This cross sectional study was conducted from January 2017 to December 2018. Four hundred fifteen
asymptomatic men who were visited by specialists, referred to Nilou laboratory in terms of high risk (HR) HPV test
testing. HR-HPV genotypes were detected using an approved assay which could discover HPV 16, HPV 18 and a
pool of other high risk HPV genotypes as well as 16+ other HR and 18 + other HR (as multiple genotypes). SPSS
software was used for statistical analysis.
Results: The mean age was 33 ± 8.14 years. Specimens were referred to the laboratory by urologists, (n = 132, 32%,
95%CI: 25.0–39.4), dermatologists, (n = 104, 25, 95% CI: 19.1–30.9), gynecologists, (n = 75, 18, 95%CI: 13.3–29.3) and
other specialists (n = 104, 25, 95% CI:19.1–30.9). The overall prevalence of other HR HPV, HPV16, HPV18 and multiple
genotypes were 54.2% (45/83), 25.3% (21/83), 3.6% (3/83) and 16.8% (14/83), respectively. The frequency of HR-HPV,
HPV16 and HPV18 genotypes was the highest among 30–40 years old.
Conclusion: The prevalence of HR-HPV infection among Iranian asymptomatic males was relatively high.
Investigation on HPV infection in men as reservoir and transmission vehicle of HPV in addition to screening in
women will improve the national public health provisions and will contribute to the application of infection control
measurements at a national level.
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Background
Human papillomavirus (HPV) is one of the most common
sexually transmitted viruses worldwide [1–3]. World Health
Organization (WHO) estimates that the global prevalence of
HPV infection is between 9 and 13% or about 630 millions.
Persistent infection with HPV is a well-established cause of
cervical cancer and there have been massive advancements
in the characterization of the natural history of cervical HPV
infection in females [4–8]. Although HPV infection in men
may be associated with low mortality and morbidity, investi-
gation remains crucial due to its association with genital
warts, penile, anorectal, and oropharyngeal cancers as well as
to the role of men in HPV transmission to their female sex-
ual partners [9–11]. It is estimated that the prevalence of
HPV-infection is 20% of all men, reaching 70% in some age
groups, especially among individuals between 15 and 24
years of age [9]. However, compared with cervical HPV in-
fection, relatively little is known about the epidemiology of
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HPV infection in men [12]. In fact, it has been suggested that
men may constitute a reservoir for inadvertently transmitting
infection to women and because of its asymptomatic nature,
therefore, contributing to the persistence of infection and
cancer [13]. Conversely, unlike women, there are no guide-
lines for screening of males and no any other regular HPV
testing does exist. Information about HPV transmission
probabilities in men is of paramount importance to evaluate
the impact of prophylactic vaccines against HPV and to
monitor the distribution of specific types before and after the
introduction of HPV vaccine [14]. Global data on age-
specific prevalence of human papillomavirus (HPV) infection
in males, especially for oncogenic HPV types 16 and 18, are
essential for future efforts to prevent HPV-related diseases,
including expanded access to HPV prophylactic vaccines for
boys and young men [15, 16]. Since HPV types 16 and 18
have been designated as conferring the greatest risk for
cervical disease, their detection may prove useful in guid-
ing patient management [17]. In this regard, the difference
in age patterning of different HPV-related diseases sug-
gests that genital HPV natural history in men varies by
age and HPV type. The objective of the current survey
was to characterize the type-specific HPV genital infection
positivity distribution in men according to age in order to
identify age ranges and genotypes that can directly endan-
ger asymptomatic men who referred to Nilou laboratory
and consequently, their partners.
Methods
Study population
This cross sectional study was conducted from January
2017 to December 2018. Four hundred and fifteen
asymptomatic heterosexual males who were mostly vis-
ited by dermatologists, gynecologists and urologists re-
ferred to Nilou laboratory in order to test HR-HPV
because of importance of detecting infected men (HR-
HPV+) as reservoir which can endanger women as their
sexual partners. A written informed consent guarantee-
ing confidentiality was taken from each patient. The
study was approved by the National Ethics Committee
for Biomedical Research affiliated to The Ministry of
Health and Medical Education. Demographic data were
recorded by trained laboratory staff.
Sampling and HPV testing
Urogenital specimens were taken from the urinary me-
atus, frenulum, glans of penis and scrotum using dry
polyester tipped or dry foam swabs. To detect HR-HPV
genotypes in patient specimens, Cobas®4800 (Roche Mo-
lecular Systems, CA, USA) was applied using oligo-
nucleotide probes labeled with four different fluorescent
dyes. The Cobas®4800 HPV test included fully auto-
mated sample preparation combined with real-time PCR
technology and software that integrated the two
modules. One milliliter aliquots of liquid specimen were
transferred to 13mL barcoded tubes provided by the
manufacturer. The Cobas®4800 HPV test was performed
according to the manufacturer’s protocol. The amplified
signals from 12 high-risk HPV types (31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66 and 68), were detected using the
same fluorescent dye, while HPV16, HPV18 and beta-
globin signals were each detected with their own appro-
priate fluorescent dye. COBAS®4800 generates individual
qualitative results for: HPV 16, HPV 18 and a pool of
other high risk HPV genotypes as well as 16+ other HR
and 18 + other HR (as multiple genotypes).
Statistics
This study shows the distribution of categorical variable
as HR-HPV genotype in men of different age groups.
The distribution of nominal variable in different groups
was tested using Cramer’s V test. Proportions were re-
ported with 95% confidence interval. P-value was calcu-
lated by using SPSS software version 22 and it was
considered significant when < 0.05.
Results
A total of 415 men referred to Nilou medical laboratory
for checking high- risk HPV were included in this sur-
vey. The mean age was 33 ± 8.14 years. The number of
men that referred to the laboratory in the order of young
to older ages were as follows: < 30 years, 120 (28.9, 95%
CI: 24.6–33.0, P value 0.542); 30–40 years, 214 (51.6,
95% CI: 24.6–33.0, P value 0.571); 40–50 years, 61 (14.7,
95% CI: 11.3–18.3, P value 0.139) and > 50 years, 20 (4.8,
95% CI: 2.9–6.7, P value 0.656) (Table 1). Results from
patients file revealed that specimens were referred to the
laboratory by urologists, (n = 132, 32, 95% CI: 25.0–
39.4), dermatologists, (n = 104, 25, 95% CI: 19.1–30.9),
gynecologists, (n = 75, 18, 95% CI: 13.3–29.3) and other
specialists, (n = 104, 25, 95% CI: 19.1–30.9) (Table 2).
Overall HR- HPV prevalence was 20%. The prevalence
of other HR HPV, HPV16, HPV18 and multiple geno-
types were 54.2% (45/83), 25.3 (21/83), 3.6% (3/83) and
16.8% (14/83) respectively (Table 1). The HR-HPV dis-
tribution according to age group was revealed in the fol-
lowing order: for < 30 years old, of 17 samples, 8 (47%),
5 (29%), 4 (32.5%) with prevalence of 1.9% (95% CI: 0.7–
3.6), 1.2% (95% CI: 0.2–2.0) and 0.9% (95% CI: 0.1–1.7)
were belonged to other HR, HPV16 and multiple geno-
types, respectively (Table 3). For 30–40 years old, out of
51 samples, 28 (55%), 13 (25%), 3 (6%) and 7 (13.7%)
with prevalence of 6.7% (95% CI: 4.5–9.1), 3.1% (95% CI:
1.4–5.0), 0.7% (95% CI: 0.1–1.3) and 1.7% (95% CI: 0.4–
3.0) were contained other HR, HPV16, HPV18 and mul-
tiple genotypes, respectively (Table 3). For 40–50 years
old, of 11 samples, 6 (55%), 3 (27%), 2(18.1%) with
prevalence of 1.4% (95% CI: 0.4–2.4), 0.7% (95% CI: 0.1–
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1.3) and 0.5% (95% CI: 0.0–1.0%) were positive for other
HR, HPV16 and multiple genotypes, respectively (Table
3). Finally, for > 50 years old, of 4 samples, 3 (75%) and 1
(25%) with prevalence of 0.7% (95% CI 0.1–1.3) and
0.2% (95% CI 0.0–0.6) were belonged to other HR and
multiple genotypes, respectively (Table 3). Prevalence of
HPV16 according to age was 1.2, 3.1 and 0.7% for < 30,
30–40 and 40–50 years old, respectively (Table 3). Only
men in the group of 30–40 years old showed to be posi-
tive for HPV18 (Table 3). Prevalence of HR HPV infections
varied according to age ranging from a maximum of 6.7% in
other HR types at age 30–40 to a minimum of 0.2% in mul-
tiple types at age > 50 (Table 3). The HR-HPV infection was
most prevalent in the group of age between 30 and 40 years
old with a rate of 3.1% for HPV16, 6.7% for the other HR
HPV types and 1.7% for multiple HPV infection (Table 3).
The calculated P-value was 0.68 for correlation intensity be-
tween HPV genotypes and age groups.
Discussion
Sexual behavior characteristics in both women and men
are of paramount impacts regarding HPV infection and
transmission. Therefore, sexual behavior of males can in-
fluence the risk of HR-HPV infection in their sexual
partners. The presence of HPV infection in men is
largely unknown. Although men are regarded as a dom-
inant factor in infection transmission to their female sex-
ual partners, they frequently do not develop clinically
significant HPV-related lesions and are usually asymp-
tomatic during relatively short lasting infections [18]. An
important issue to note is that, the infected males are
not aware of the disease due to the absence of symptoms
that endanger both themselves and their sex partners
leading to the risk for HPV-related diseases including
cancers. The prevalence of HR-HPV infection among
asymptomatic men in previous studies were included in
39, 14.3, 8.7, 20 and 9.5% in Croatia [19], Poland [18],
Mexico [14], Lithuania [20] and Iran [4] respectively
(Table 4). The prevalence of genital HPV infections in
men varies widely due to differences in the populations
studied, sampling sites, HPV DNA detection method
used, race, age, sexual orientation and circumcision [21].
In our study, HR-HPV was highly prevalent, with
20% of men testing positive for HR-HPV (Table 1).
These results were among the high range of HR-
HPV prevalence from above-mentioned regions.
Moreover the present study showed that of overall
HR-HPV prevalence, the frequency of other HR
HPV, HPV16 and HPV18 were 54.2, 25.3 and 3.6%,
respectively. On the other hand Salehi-Vaziri et al.
in 2015 reported a prevalence of HR-HPV in 9.5%
of Iranian men referred to the Sexually Transmit-
ted Infections (STI) clinics showing a prevalence of
HR HPV, HPV16 and HPV 18 were 63, 23.9 and
19.5% (Table 4).
Table 1 Demographic and HPV genotypic characteristics of patients
Characteristic All sample
n (%)
P value CI 95% (for Age and HPV ± genotype)
415 (100) α =0.05 Lower - Upper
Age
< 30 120 (28.9) 0.542 24.6–33.0%
30–40 214 (51.6) 0.571 47.0 –56.6%
40–50 61 (14.7) 0.139 11.3–18.3%
> 50 20 (4.8) 0.656 2.9–6.7%
HPV Genotyping Results
Negative 332 (80.0) < 0.005 76.4–83.8%
Positive (Total) 83 (20) < 0.005 16.4–23.9%
16 21 (25.3) 0.043 16.9–34.9%
18 3 (3.6) _ a 0.0–8.4%
Other HR 45 (54.2) 0.092 44.6–62.1%
Multipleb 14 (16.8) 0.013 9.6–25.3%
aValue could not be calculated
b16 + Other HR,18+ Other HR,16 + 18
Table 2 Distribution of specialists that referred men to Nilou
lab (N = 415)
Specialist Frequency (%) 95% Confidence Interval
Lower Upper
Urologist 132 32 25.0 39.4
Dermatologist 104 25 19.1 30.9
Gynecologist 75 18 13.3 23.9
Other 104 25 19.1 30.9
Total 415 100.0 100.0 100.0
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Therefore, unlike our report, their survey showed that
HPV18 was more prevalent among Iranian males. The
prevalence of multiple genotypes was also comparable
among ours and Salehi-Vaziri studies, 16.8 and 8.7% re-
spectively (results not shown). These differences could be
related to the sampling bias referred to STI clinic and the
difference between HPV genotype detection methods. The
results of both studies showed that the more vulnerable
age groups for HR HPV were young males between of 30
and 40 years old. Age group > 50 showed the lowest preva-
lence of HR-HPV, however, the small sample size in this
group avoid us to draw a definite conclusion. Overall cor-
relation intensity between HPV genotypes and age groups
was not significant (P-value = 0.68).
There are not too many reports in terms of men refer-
ral system from specialist doctors to medical laborator-
ies. Our study showed that urologists (32%),
dermatologists (25%) and gynecologists (18%) had a
higher percentage in referring men to the Nilou labora-
tory for HPV testing. From public health point of view,
this finding can have a significant impact on targeting
the most-visiting specialist for getting access to detect
infected males across the country.
According to the World Health Organization (WHO)
draft published in 2019, the message entitled “global
strategy toward the elimination of cervical cancer as
public health problem” was considered as a global strat-
egy for comprehensive, population-based approach to
encourage all countries for the elimination of cervical
cancer. This policy incorporates the vaccination and
other public health issues on females. Therefore, recog-
nition of HPV infection in men as a vehicle for HPV
transmission in females could impact the implementa-
tion of preventive measures for cervical cancer and other
HPV-related diseases in both genders. Protective mea-
sures like HPV vaccination in men will not only care for
Table 3 Characteristic of HPV genotypes Frequency according to age groups and Prevalence of HPV infection among men (N =
415)
Age Na HPV genotype HPV + genotype Frequency HPV + genotype (%) No.HPV types Prevalence (95%CI)
(N = 415)















Total 17 100 17 4.0 (2.4–6.2%)




















Total 51 100 51 12.2 (9.1–15.1%)















Total 11 100 11 2.6%(1.2–4.3%)










Total 4 100 4 0.9% (0.1–1.7%)
Total 415 Total 83
a Number of age groups
b16 + Other HR,18+ Other HR,16 + 18
Table 4 Reported HR HPV distribution among referral asymptomatic men from different surveys
Author/ Year Country HR-HPV genotype prevalence
Total (%) 16 (%) 18 (%) Other HR (%)
Jersovein et al. [20]/2019 Lituania 20 15 0 70
Bosnjak Z et al. [19]/2013 Croatia 39 17.8 1.3 28.2
Parada et al. [14] /2010 Mexico 8.7 13.6 15.9 70.4
Dutkiewiczet al [18]./2013 Poland 14.3 14.4 _a _
Salehi-Vaziri et al. [4]/2015 Iran 9.5 23.9 19.5 63
Present Study/2019 Iran 20 25.3 3.6 54.2
a Genotype prevalence could not be written
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them but will also benefit their sexual partners. There-
fore, policies to mitigate HPV infections in couples may
give rise in public health improvement.
Conclusion
The results of the current study showed that the preva-
lence of HR-HPV infection among Iranian asymptomatic
males was relatively high. Therefore, a survey of HPV in-
fection in men as reservoir and transmission vehicle of
HPV in addition to screening in women will improve
the national public health provisions and will contribute
to the application of infection control measurements at
a national level.
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